Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Med‑tech maker urges higher Medicaid implant payments for VNS therapy, cites cost‑savings
Summary
LivaNova, maker of VNS Therapy, told the Senate Medicaid subcommittee a modest payment increase for the implant could improve access for Ohio Medicaid members with drug‑resistant epilepsy and said a five‑year budget model could yield state net savings.
Tim Sweeney, representing LivaNova, a manufacturer of vagus nerve stimulation (VNS) therapy, told the Senate Medicaid subcommittee that increasing Medicaid hospital payments for the implant procedure could expand access for Ohioans with drug‑resistant epilepsy and produce net savings to the Medicaid program.
Sweeney described VNS therapy as an implantable neuromodulation…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
